Publication Date
11-2023
Files
Download Full Text (236 KB)
Abstract
Investigating the Association between Mast Cell Activation Syndrome and Irritable Bowel Syndrome Introduction Mast Cell Activation Syndrome (MCAS) involves the inappropriate release of chemical mediators resulting in varied episodic symptoms. Irritable Bowel Syndrome (IBS) is a common functional abdominal disorder where mucosal immune alterations play a key role. Since mast cells function as gatekeepers for the intestinal interface, we examined what proportion of patients diagnosed with MCAS also had IBS along with comorbid risk factors. Methods All patients in our study were 18 years of age or older. We used Cerner Healthfacts to gather our cohorts of patients with MCAS, IBS. We examined potential comorbid risk factors for MCAS using multivariable regression. Results We identified 2,508 patients with MCAS, mean age of48.7 ± 17.7 years with 67.7% (1,698) being female. 79.9% (2,003) were Caucasian, 8.3% (209) were African American. 11.5% (288/2,508) of patients with MCAS had IBS as well. The most common comorbid autoimmune disorder (AiD) was autoimmune thyroid disease (220). On multivariable regression, the factors associated with a higher risk of IBS in those with MCAS included cholestatic liver disease (OR 9.95), depression (OR 2.03), anxiety (OR 1.73), female gender (OR 1.64), autoimmune disorders (OR 1.63), and asthma (OR 1.56). Conclusions MCAS and IBS have symptom overlap with diarrhea and abdominal cramping. 11.48% of MCAS patients had IBS, indicating it may be worthwhile to inquire about bowel habits. Clinicians should also consider autoimmune thyroid disease in MCAS patients. There may be merit in exploring IBS therapies for MCAS patients.
Disciplines
Allergy and Immunology | Pediatrics
Recommended Citation
Jakhar, Ishaan; Urschler, Maggie; Singh, Medha; Sahil, Suman; and Ahmad, Hassan, "Investigating the Association between Mast Cell Activation Syndrome and Irritable Bowel Syndrome" (2023). Posters. 362.
https://scholarlyexchange.childrensmercy.org/posters/362
Notes
Presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2023 Annual Scientific Meeting; Anaheim, California; November 9-13th, 2023.